According to CTV (12/7/15), a class-action lawsuit has been filed against GlaxoSmithKline, maker of Zofran, alleging babies were put at risk of birth defects when they were exposed to a drug not approved for use in pregnant women. The plaintiffs, approximately a dozen so far, say they were not warned that there was the potential for birth defects.
One such plaintiff is Terra Mercer, whose daughter Aaleyah, was born with a cleft lip and cleft palate after Mercer was prescribed Zofran off label to treat her morning sickness. In Canada, Zofran’s warning label states, “the safety of ondansetron for use in human pregnancy has not been established. Ondansetron is not teratogenic in animals. However, as animal studies are not always predictive of human response, the use of ondansetron in pregnancy is not recommended.”
According to CBS11 (7/23/15), in GlaxoSmithKline’s own filings with Health Canada, the drugmaker noted Zofran was “not recommended” for pregnant women. GlaxoSmithKline responded to CBS noting it had used the “specific wording that the Canadian government requires for such products, and Zofran sold in the United States has the language mandated under the U.S. code.”
READ MORE ZOFRAN BIRTH DEFECT LEGAL NEWS
Court documents filed in a US lawsuit (Flynn v. GlaxoSmithKline, case number 2:15-cv-00709) against GlaxoSmithKline allege the drugmaker chose not to study Zofran in women because animal studies revealed evidence of birth defects and intrauterine deaths in offspring.
“GSK avoided conducting these studies because they would have hampered its marketing of Zofran and decreased profits by linking the drug to serious birth defects,” court documents allege.
“GSK’s conduct was tantamount to using expectant mothers and their unborn children as human guinea pigs.”
Ondansetron is approved to treat nausea and vomiting in patients who are undergoing chemotherapy, but doctors are able to prescribe it off label.